|
|
 Previous Article | Table of Contents | Next Article 
Prognostic importance of mutations in the ras proto-oncogenes in de novo
acute myeloid leukemia
A Neubauer, RK Dodge, SL George, FR Davey, RT Silver, CA Schiffer, RJ Mayer, ED Ball, D Wurster-Hill and CD Bloomfield
Department of Medicine, Lineberger Cancer Research Center, University of
North Carolina at Chapel Hill 27599-7295.
Mutations of the N- and K-ras genes are the most frequent genetic
aberrations in acute myeloid leukemia (AML) and their detection in
preleukemic conditions such as the myelodysplastic syndrome (MDS) suggests
a role in the earliest phases of leukemogenesis. Despite these
observations, little is known about the clinical importance of ras
mutations in AML. We studied the clinical impact of ras mutations in 99
patients with de novo AML. All patients were treated in two prospective
multicenter trials. The polymerase chain reaction was used to amplify areas
surrounding the codons 12, 13, and 61 of the three ras genes N-, K-, and
H-ras from DNA from bone marrow cells, ras mutations were detected by an
algorithm based on allele-specific oligonucleotide hybridization. Eighteen
of 99 (18%) patients harbored mutations in either N- or K-ras. All of the
observed mutations occurred in N-ras (N = 10) and K-ras (N = 5) or
concurrently in both N- and K-ras (N = 3). There were no significant
differences between ras-negative and ras- positive patients according to
age, sex, blood counts, cytogenetic abnormalities, or
French-American-British classification. However, univariate analysis
suggested a longer survival in ras-positive patients (P = .11). When
adjusted for age, which was the most important factor affecting outcome,
the presence of a ras mutation emerged as a significant predictor for
improved survival (P = .03) and along with lower bone marrow blast counts
(P = .02) and better cytogenetic category (P = .01). However, the presence
of an aberrant ras allele was strongly correlated with lower bone marrow
blast counts (P = .007). Thus, whether a mutation in the N-ras or K-ras
proto-oncogenes directly affects treatment outcome or indirectly through an
association with lower leukemic burden remains to be determined.
Nevertheless, these findings counter the prevailing bias that oncogene
mutations lead to more aggressive behavior in human malignancies.
Volume 83,
Issue 6,
pp. 1603-1611,
03/15/1994
Copyright © 1994 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
U. Bacher, T. Haferlach, W. Kern, C. Haferlach, and S. Schnittger
A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia
Haematologica,
June 1, 2007;
92(6):
744 - 752.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Bloomfield, K. Mrozek, and M. A. Caligiuri
Cancer and Leukemia Group B Leukemia Correlative Science Committee: Major Accomplishments and Future Directions.
Clin. Cancer Res.,
June 1, 2006;
12(11):
3564s - 3571s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Bacher, T. Haferlach, C. Schoch, W. Kern, and S. Schnittger
Implications of NRAS mutations in AML: a study of 2502 patients
Blood,
May 15, 2006;
107(10):
3847 - 3853.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. F. Goemans, C. M. Zwaan, A. Harlow, A. H. Loonen, B. E. S. Gibson, K. Hahlen, D. Reinhardt, U. Creutzig, M. C. Heinrich, and G. J. L. Kaspers
In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets
Blood,
November 15, 2005;
106(10):
3532 - 3537.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Suzuki, H. Kiyoi, K. Ozeki, A. Tomita, S. Yamaji, R. Suzuki, Y. Kodera, S. Miyawaki, N. Asou, K. Kuriyama, et al.
Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia
Blood,
October 15, 2005;
106(8):
2854 - 2861.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. T. Bowen, M. E. Frew, R. Hills, R. E. Gale, K. Wheatley, M. J. Groves, S. E. Langabeer, P. D. Kottaridis, A. V. Moorman, A. K. Burnett, et al.
RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years
Blood,
September 15, 2005;
106(6):
2113 - 2119.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Frohling, C. Scholl, D. G. Gilliland, and R. L. Levine
Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications
J. Clin. Oncol.,
September 10, 2005;
23(26):
6285 - 6295.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Bullinger and P. J.M. Valk
Gene Expression Profiling in Acute Myeloid Leukemia
J. Clin. Oncol.,
September 10, 2005;
23(26):
6296 - 6305.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Illmer, C. Thiede, A. Fredersdorf, S. Stadler, A. Neubauer, G. Ehninger, and M. Schaich
Activation of the RAS Pathway Is Predictive for a Chemosensitive Phenotype of Acute Myelogenous Leukemia Blasts
Clin. Cancer Res.,
May 1, 2005;
11(9):
3217 - 3224.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Passioura, A. Dolnikov, S. Shen, and G. Symonds
N-Ras-Induced Growth Suppression of Myeloid Cells Is Mediated by IRF-1
Cancer Res.,
February 1, 2005;
65(3):
797 - 804.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Allan, A. G. Smith, K. Wheatley, R. K. Hills, L. B. Travis, D. A. Hill, D. M. Swirsky, G. J. Morgan, and C. P. Wild
Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy
Blood,
December 15, 2004;
104(13):
3872 - 3877.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. F. V. Woude, G. J. Kelloff, R. W. Ruddon, H.-M. Koo, C. C. Sigman, J. C. Barrett, R. W. Day, A. P. Dicker, R. S. Kerbel, D. R. Parkinson, et al.
Reanalysis of Cancer Drugs: Old Drugs, New Tricks
Clin. Cancer Res.,
June 1, 2004;
10(11):
3897 - 3907.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Ozeki, H. Kiyoi, Y. Hirose, M. Iwai, M. Ninomiya, Y. Kodera, S. Miyawaki, K. Kuriyama, C. Shimazaki, H. Akiyama, et al.
Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia
Blood,
March 1, 2004;
103(5):
1901 - 1908.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Lancet and J. E. Karp
Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy
Blood,
December 1, 2003;
102(12):
3880 - 3889.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Clark, L. Zhong, D. Filiault, S. Perman, Z. Ren, M. Gould, and X. Yang
Anti-Leukemia Effect of Perillyl Alcohol in Bcr/Abl-Transformed Cells Indirectly Inhibits Signaling through Mek in a Ras- and Raf-Independent Fashion
Clin. Cancer Res.,
October 1, 2003;
9(12):
4494 - 4504.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Inokuchi, H. Yamaguchi, H. Hanawa, S. Tanosaki, K. Nakamura, M. Tarusawa, K. Miyake, T. Shimada, and K. Dan
Loss of DCC Gene Expression Is of Prognostic Importance in Acute Myelogenous Leukemia
Clin. Cancer Res.,
June 1, 2002;
8(6):
1882 - 1888.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Prix, P. Uciechowski, B. Bockmann, M. Giesing, and A. J. Schuetz
Diagnostic Biochip Array for Fast and Sensitive Detection of K-ras Mutations in Stool
Clin. Chem.,
March 1, 2002;
48(3):
428 - 435.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Karp, J. E. Lancet, S. H. Kaufmann, D. W. End, J. J. Wright, K. Bol, I. Horak, M. L. Tidwell, J. Liesveld, T. J. Kottke, et al.
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial
Blood,
June 1, 2001;
97(11):
3361 - 3369.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Stirewalt, K. J. Kopecky, S. Meshinchi, F. R. Appelbaum, M. L. Slovak, C. L. Willman, and J. P. Radich
FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia
Blood,
June 1, 2001;
97(11):
3589 - 3595.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Toyota, K. J. Kopecky, M.-O. Toyota, K.-W. Jair, C. L. Willman, and J.-P. J. Issa
Methylation profiling in acute myeloid leukemia
Blood,
May 1, 2001;
97(9):
2823 - 2829.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Yamamoto, H. Kiyoi, Y. Nakano, R. Suzuki, Y. Kodera, S. Miyawaki, N. Asou, K. Kuriyama, F. Yagasaki, C. Shimazaki, et al.
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Blood,
April 15, 2001;
97(8):
2434 - 2439.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. D. Sorenson
Detection of Mutated KRAS2 Sequences as Tumor Markers in Plasma/Serum of Patients with Gastrointestinal Cancer
Clin. Cancer Res.,
June 1, 2000;
6(6):
2129 - 2137.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
H.-M. Koo, M. J. McWilliams, W. G. Alvord, and G. F. Vande Woude
Ras Oncogene-Induced Sensitization to 1-{{beta}}-D-Arabinofuranosylcytosine
Cancer Res.,
December 1, 1999;
59(24):
6057 - 6062.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kiyoi, T. Naoe, Y. Nakano, S. Yokota, S. Minami, S. Miyawaki, N. Asou, K. Kuriyama, I. Jinnai, C. Shimazaki, et al.
Prognostic Implication of FLT3 and N-RAS Gene Mutations in Acute Myeloid Leukemia
Blood,
May 1, 1999;
93(9):
3074 - 3080.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Beaupre and R. Kurzrock
RAS and Leukemia: From Basic Mechanisms to Gene-Directed Therapy
J. Clin. Oncol.,
March 1, 1999;
17(3):
1071 - 1071.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-M. Koo, M. Gray-Goodrich, G. Kohlhagen, M. J. McWilliams, M. Jeffers, A. Vaigro-Wolff, W. G. Alvord, A. Monks, K. D. Paull, Y. Pommier, et al.
The ras Oncogene-Mediated Sensitization of Human Cells to Topoisomerase II Inhibitor-Induced Apoptosis
J Natl Cancer Inst,
February 3, 1999;
91(3):
236 - 244.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
